Please login to the form below

Hydroxychloroquine

This page shows the latest Hydroxychloroquine news and features for those working in and with pharma, biotech and healthcare.

Speed kills

On 22 May, The Lancet published a research paper about hydroxychloroquine, the antimalarial drug, as a potential treatment for COVID-19. ... claimed that the use of hydroxychloroquine carried a greater risk of heart arrhythmia and death.

Latest news

WHO takes stock of global COVID-19 R&D progress

The WHO also took the decision to discontinue the Solidarity Trial’s hydroxychloroquine and lopinavir/ritonavir arms following a review of evidence obtained at the interim analysis. ... These results showed that neither hydroxychloroquine nor
FDA grants emergency authorisation to chloroquine for COVID-19

This data supports earlier preliminary results from a small study of hydroxychloroquine in combination with the antibiotic azithromycin, and as a monotherapy. ... Although the drug was effective on its own, when added to the antibiotic azithromycin,
Novartis donates malaria drug for COVID-19 clinical trials

The drug, hydroxychloroquine, as well as a related drug, chloroquine, are currently being evaluated for use against COVID-19 in clinical trials around the world. ... Hydroxychloroquine is a derivative of chloroquine, and is less toxic form of the latter
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace

hydroxychloroquine – could be a treatment option. ... It has been suggested that hydroxychloroquine may be able to reduce the duration of infection in patients with mild-to-moderate disease, cutting the number of patients who tested positive for
Benlysta granted priority FDA review

Benlysta is used with standard of care treatment, including Plaquenil (hydroxychloroquine), methotrexate, steroids, and immunosuppressants such as mycophenalate.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

COVID-19: the race to find a vaccine

Other antivirals including hydroxychloroquine – a drug championed by President Donald Trump – and favipiravir are also in clinical development, raising hopes that researchers will find a drug with some level of efficacy
As COVID-19 takes over the world, biopharma fights back

A standard malaria treatment: chloroquine and hydroxychloroquine. A decades-old antimalaria drug, chloroquine, entered the global spotlight in March after US President Donald Trump touted it as a potentially effective coronavirus ... treatment. Since then

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...